Glucagon-like peptide-1 receptor agonists, which include Ozempic and Mounjaro, cost between five to 10 times more in the U.S. than other wealthy nations, according to research KFF published Aug. 17.
Read the full post on Becker's Hospital Review - Healthcare News
